Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Talquetamab

Review the clinical trials studying talquetamab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-12 of 12

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
Status: Active
Location: 28 locations
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Status: Active
Location: 20 locations
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
Status: Active
Location: 8 locations
A Study of Talquetamab for Treating Patients with Relapsed or Refractory Multiple Myeloma who have Received BCMA CAR T-Cell Therapy
Status: Active
Location: 7 locations
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 5 locations
Talquetamab with or without Daratumumab for the Treatment of Relapsed or Refractory Multiple Myeloma in Older Adults
Status: Active
Location: 3 locations
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
Status: Active
Location: 3 locations
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Talquetamab and Lenalidomide for Post Stem Cell Transplant Maintenance Therapy for Patients with Multiple Myeloma
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Talquetamab with or without Teclistamab for the Treatment of Newly Diagnosed Multiple Myeloma, ROTATE Trial
Status: Active
Location: Yale University, New Haven, Connecticut
External Beam Radiation Therapy in Combination with Talquetamab for the Treatment of Multiple Myeloma Patients with Extramedullary Disease
Status: Active
Location: City of Hope Comprehensive Cancer Center, Duarte, California
Talquetamab in Combination with Iberdomide and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Location: University of California San Francisco, San Francisco, California